CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer

Core Insights - CytoDyn Inc. has appointed Robert E. Hoffman as Chief Financial Officer, effective May 15, 2025, succeeding Mitch Cohen who served in an interim capacity since February 2024 [1][4] Group 1: Leadership Transition - Robert E. Hoffman is an experienced industry veteran with decades of financial and leadership experience in the biotech sector, having held various executive roles [2] - Hoffman previously served as President, CEO, interim CFO, and Chairperson of Kintara Therapeutics, and has held CFO positions at Heron Therapeutics, Innovus Pharmaceuticals, and AnaptysBio [2] - The transition aims to support CytoDyn's clinical development pipeline, particularly in oncology, with Hoffman bringing critical financial and capital markets expertise [4] Group 2: Company Overview - CytoDyn is a clinical-stage biotechnology company focused on developing leronlimab, a humanized IgG4 monoclonal antibody targeting CCR5, which is involved in various disease processes [5] - The company has explored leronlimab in multiple therapeutic areas, including infectious diseases, oncology, and autoimmune conditions [5]